Clinical Trial Finder | Pancreatic Cancer Action Network

Back to Trial Search

A Phase I/IIa, Open-Label, Multicenter, Nonrandomized, Safety and Anti-tumor Activity Study of IMM-1-104, a Novel Oral Dual MEK1/2 Inhibitor in Participants With Previously Treated RAS-Mutated Advanced or Metastatic Solid Tumors

Summary

The purpose of this phase I/IIa trial is to determine the safety of IMM-1-104 when administered as monotherapy in patients with RAS-mutated advanced or metastatic solid tumors, including pancreatic cancer.

General Information

NCT#: NCT05585320
Study ID: IMM1104-101
Trial Phase: Phase I/II

Trial Sponsor: Immuneering Corporation
Therapies Used in This Trial: IMM-1-104

Request a Healthcare Provider account to access Trial Eligibility and Site Information.

View Details

An authorized Healthcare Provider account is required to access Trial Eligibility and Site Information. Already have an account? Sign In

Request an Account

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account.
In order to view this information, you need to be signed in as a Health Care Provider.
In order to see the trial eligibility criteria, you need to be signed in as a Health Care Provider.
This information is restricted to validated Health Care Providers.

Eligibility

-------------------------------------------------------------------------------------------

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account by clicking on the Request button.
------------------------------------------------------------------------------------------------------
In order to view this information, you need to be signed in as a Health Care Provider. You are currently not authorized.

Site Information

Back to Trial Search